Clinigen Group (CLIN) Sets New 1-Year High at $1,060.00

Clinigen Group PLC (LON:CLIN) hit a new 52-week high on Thursday . The stock traded as high as GBX 1,060 ($13.85) and last traded at GBX 998 ($13.04), with a volume of 166752 shares. The stock had previously closed at GBX 1,014 ($13.25).

Several equities research analysts recently weighed in on CLIN shares. Peel Hunt reissued a “buy” rating on shares of Clinigen Group in a report on Friday, February 1st. Royal Bank of Canada reissued a “top pick” rating and issued a GBX 1,640 ($21.43) price objective (up previously from GBX 1,470 ($19.21)) on shares of Clinigen Group in a report on Wednesday, February 27th. Finally, Numis Securities reissued a “buy” rating and issued a GBX 1,275 ($16.66) price objective on shares of Clinigen Group in a report on Wednesday, February 27th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Clinigen Group has an average rating of “Buy” and an average target price of GBX 1,325 ($17.31).

The company has a debt-to-equity ratio of 56.71, a current ratio of 1.54 and a quick ratio of 1.32. The company has a market capitalization of $1.37 billion and a P/E ratio of 51.91.

WARNING: This report was published by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at

About Clinigen Group (LON:CLIN)

Clinigen Group plc operates as a specialty pharmaceutical and services company. The company operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines in the Africa and Asia Pacific region.

See Also: Do equity income investments outperform growth and income investments?

Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with's FREE daily email newsletter.